KUR 112
Alternative Names: I-040302Latest Information Update: 02 Oct 2021
Price :
$50 *
At a glance
- Originator Kuros Biosurgery
- Developer Kuros Biosciences
- Class Blood proteins; Peptide hormones; Recombinant fusion proteins
- Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bone cysts
Most Recent Events
- 28 Aug 2019 No recent reports of development identified for phase-I development in Bone-cysts in Switzerland (Intralesional, Injection)
- 20 Oct 2016 KUR 112 receives Rare Paediatric Disease designation for Solitary bone cysts in USA
- 16 Jul 2016 No recent reports of development identified for phase-I development in Bone-cysts in Switzerland (Intralesional, Injection)